Linsitinib
http://dbpedia.org/resource/Linsitinib an entity of type: Thing
Linsitinib é uma droga experimental camndidata ao tratamento de vários tipos de câncer. É uma enzima inicidora do IGF-1R. Ela previne a proliferação celular. è de uso oral. Linsitinib está em Fase III de pesquisa para carcinoma de supra-renal e fase II para cancer pulmonar e ovariano.
rdf:langString
Linsitinib is an experimental drug candidate for the treatment of various types of cancer. It is an inhibitor of the insulin receptor and of the insulin-like growth factor 1 receptor (IGF-1R). This prevents tumor cell proliferation and induces tumor cell apoptosis. Linsitinib was granted orphan drug designation for adrenocortical carcinoma in March 2012.
rdf:langString
rdf:langString
Linsitinib
rdf:langString
Linsitinib
xsd:integer
37339814
xsd:integer
1055463828
rdf:langString
Linsitinib.svg
xsd:integer
180
rdf:langString
OSI-906
xsd:integer
-3
rdf:langString
Linsitinib is an experimental drug candidate for the treatment of various types of cancer. It is an inhibitor of the insulin receptor and of the insulin-like growth factor 1 receptor (IGF-1R). This prevents tumor cell proliferation and induces tumor cell apoptosis. Linsitinib was granted orphan drug designation for adrenocortical carcinoma in March 2012. Phase II clinical trials were initiated for multiple myeloma, ovarian cancer, hepatocellular carcinoma, and NSCLC, but subsatisfactory results caused research for these indications to be discontinued. A phase III clinical trial found that linsitinib did not increase survival in patients with adrenocortical carcinoma. As of 2017, no clinical trials were in progress.
rdf:langString
Linsitinib é uma droga experimental camndidata ao tratamento de vários tipos de câncer. É uma enzima inicidora do IGF-1R. Ela previne a proliferação celular. è de uso oral. Linsitinib está em Fase III de pesquisa para carcinoma de supra-renal e fase II para cancer pulmonar e ovariano.
xsd:nonNegativeInteger
4339
rdf:langString
OSI-906
rdf:langString
(1s,3s)-3-[8-Amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol